Verdier Eye Center, PLC is still gathering data on patients currently enrolled through their two year post-op period. This study is ongoing, but no currently recruiting participants. The purpose of this study is to determine the effectiveness of collagen cross-linking in the cornea in halting the progression and possibly partially reversing the effects of keratoconus. Keratoconus is a progressive weakening in the cornea that causes irregular astigmatism and thinning of the cornea. The overall effect is reduction of vision, and in more advanced cases, scarring of the cornea that may lead to the need for corneal transplantation. Cross linking has been shown to increase the rigidity of the cornea. The patients would be treated once and then followed over 24 months. The goal for the two groups of apporximately 66 patients to be included in the study. One eye from the first group will undergo treatment, while the second of age matched indviduals will serve as a control. The study will be a prospective, randomized, blinded study which will include a treatment group and a placebo group. The treatment uses a combination of topical Riboflavin and UV light applied directly to the cornea. Riboflavin and UV light work together to promote cross-linking of the corneal collagen fibrils, which we believe helps strengthen and stabilize the cornea. Previous studies conducted in Italy and Germany have shown corneal flattening following treatment and a reduction in disease progression. We are excited to be part of the continuing investigations in the United States.
If you are interested in learning more about the study or think you may be a candidate, please contact Paula at our office 616-949-2001.